

REAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS



C. MONTERO-VILCHEZ¹, M.I. ARCHILLA AMAT¹, M.R. CANTUDO CUENCA¹, MI. SIERRA TORRES¹, L MARTINEZ DUEÑAS LOPEZ MARÍN¹, A. JIMENEZ MORALES¹.

¹VIRGEN DE LAS NIEVES UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, GRANADA, SPAIN.

BACKGROUND AND IMPORTANCE:

Guselkumab is a monoclonal antibody that selectively binds to interleukin 23 protein with a label indication in plaque psoriasis and psoriatic arthritis (PsA). Very little information about the real-world persistence with guselkumab therapy for PsA is known.

AIM AND OBJECTIVES

The aim is to evaluate persistence with guselkumab therapy in PsA.

MATERIAL AND METHODS

Retrospective, observational, unicenter study

Variables:

Sex
Age
Comorbidities
Previous treatments
Start-end date



Date first guselkumab dose

May
2020

third level hospital


September
2023

* Excluded: Patients with less than nine months treatment duration





RESULTS


69 patients




50 patients met Inclusion criteria



Age: 53.3 (12.70 SD) years



Use of an anti-TNF drug: 74% (37/50)



Persistence:

52% of patients experienced the event within 30 months of treatment

Mean drug survival: 20.6 (2.7 SD) months

Mean drug survival:

- Use Anti-TNF: 16.4 (1.8 SD) months
- No Anti-TNF: 26.0 (2.0 SD) months
 $p=0.020$

CONCLUSION AND RELEVANCE

As in clinical trials and another real-world study, high persistence rates were observed with guselkumab during the first year. Further real-world research should be conducted to correlate the differences found between patients with previous anti-TNF treatment, as no such differences were found in clinical trials.

